The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-Unilife, Apple, Sony, Oncolytics, Biodel, BlackBerry

Mon, 09th Sep 2013 12:46

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Sept. 9 (Reuters) - Some U.S. stocks to watch on Monday:

FUTURES RISE AFTER CHINA DATA; SYRIA CONCERNS REMAIN

U.S. stock index futures advanced in the wake of upbeateconomic data from China, though concerns remained about apotential strike against Syria. S&P 500 futures rose 3.3points and were above fair value, a formula that evaluatespricing by taking into account interest rates, dividends andtime to expiration on the contract. Dow Jones industrial averagefutures gained 32 points, and Nasdaq 100 futures added 14 points.

** APPLE INC, Friday close $498.22, up 1.2 pctpremarket

Brokerage FBN Securities raised its price target on thecompany's stock to $600 from $575 in anticipation of Applemaking an announcement of its iPhone 5S and iPhone 5C onTuesday. The brokerage said it expected the phones to startshipping on Sept. 20. FBN sees the iPhone 5C as an opportunityfor Apple to be successful in China.

** UNILIFE CORP, Friday close $3.07, up 25 pctpremarket

The medical device maker said it entered into a long-termcontract to supply pre-filled syringes to Sanofi SA for use with Sanofi's thrombosis drug, Lovenox.

In addition to future revenue from the sale of the syringes,Unilife may receive up to $15 million from Sanofi in milestonepayments, with $5 million expected in 2013. The contract periodcan extend up to 2024.

** ONCOLYTICS BIOTECH INC, Friday close $2.65, up17 pct premarket

The company said its cancer drug, Reolysin, reduced the sizeof tumors in 92 percent of lung cancer patients in a mid-stagetrial.

** BIODEL INC, Friday close $5.03, up 12 pctpremarket

The pharmaceutical company said on Sunday that preliminarydata showed its fast-acting regular human insulin BIOD-123 metits goal in a mid-stage trial.

** ISIS PHARMACEUTICALS INC, Friday close $27.92,up 7 pct premarket

Biogen Idec Inc has agreed to pay another $100million upfront to the drugmaker as a part of a broadcollaboration to develop new medicines for neurologicaldisorders, the companies said.

** DELTA AIRLINES, Friday close $19.89, up 5 pctpremarket

The U.S. airline will join the S&P 500 index after the closeof trading on Sept. 10, replacing BMC Software, Standard& Poor's said on Friday.

** BLACKBERRY LTD, Friday close $10.84, up 4.3 pctpremarket

The company's largest shareholder, Prem Watsa, has assembledbillions in backing from Canada's biggest pension funds for abid, The Sunday Times reported on Sunday. (http://link.reuters.com/caz82v)

Watsa is the founder and chairman of Fairfax FinancialHoldings Ltd that holds about 10 percent stake in the company.

** SMITHFIELD FOODS INC, Friday close $33.92, up 2pct after market

The U.S. Committee on Foreign Investment has cleared the wayfor Shuanghui International Holdings Ltd's proposed $4.7 billionacquisition of Smithfield Foods, the companiessaid.

** NETAPP INC, Friday close $42.24, up 2.8 pctpremarket

Brokerage UBS Investment Research raised its rating on thedata storage equipment maker's stock to "buy" from "neutral,"according to the website Theflyonthewall.com.

** JOHNSON & JOHNSON, Friday close $87.16, up 1 pctpremarket

The company has launched a sale process for its OrthoClinical Diagnostics unit, which makes blood screening equipmentand laboratory blood tests and could fetch around $5 billion.J&J has asked JPMorgan Chase & Co to run the sale and ispreparing to send detailed financial information in coming weeksto potential buyers.

** VODAFONE PLC, Friday close $32.89

The company may fail to reach the 75 percent threshold ofacceptances from shareholders needed to clinch Germany's largestcable operator Kabel Deutschland, the Financial Timessaid. Vodafone agreed a 7.7 billion euro ($10.13 billion) offerfor Kabel Deutschland in June, a near 40 percent premium toKabel's share price before its interest first emerged.

** SONY CORP, Friday close $21.02, down 2 pct aftermarket

The electronics maker announced the Japanese release of itsPlayStation 4 on Monday as the company braces for a gamingconsole war with Microsoft Corp that could make orbreak the Japanese firm's struggle to return to profit.

** GLAXOSMITHKLINE PLC, Friday close $51.67

Japan's Suntory Beverage & Food Ltd is to buyGlaxoSmithKline's Lucozade and Ribena brands for 1.35 billionpounds ($2.11 billion) to expand into new markets.

** GOOGLE INC, Friday close $879.58

The U.S. government tapped into computer networks ofcompanies including Google and Brazilian state-run oil firmPetroleo Brasileiro SA, according to leaked U.S.documents aired by Globo, Brazil's biggest television network.

** TIME WARNER INC, Friday close $61.45

The entertainment company is planning to transfer its U.S.retirees from company-sponsored health plans and move them toprivate insurance exchanges. According to an August memoobtained by Reuters, the media company will make allocations toa Health Reimbursement Arrangement account for retirees to usetowards the purchase of coverage on an exchange. Previously,Time Warner provided an indirect subsidy through a supplementaryMedicare program. (Compiled by Varun Aggarwal; Editing by Kirti Pandey)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.